MA has restated its disappointment at the health department's failure to consult on the attempt to defer submissions from consideration at the March PBAC meeting following the release of advice that shows officials advised Mark Butler it was "critical" to "mitigate" the reputational risks to the government.
'We are very unhappy that we were not consulted as it is an expectation'
December 3, 2024 Latest NewsBioPharmaNews of the Day
Latest Video
New Stories
-
Sanofi building an AI-literate organisation through expectations, over experiments
November 14, 2025 - - Latest News -
The four 'H' words that can help drive the adoption of AI in health
November 14, 2025 - - Latest News -
Immutep posts encouraging Phase 2 results as 'Efti' spurs robust anti-tumour activity
November 13, 2025 - - Australian Biotech -
PYC Therapeutics appoints Peter Coleman as new Chair as part of board renewal
November 13, 2025 - - Australian Biotech -
New gene discoveries improve diagnosis of inherited heart disease
November 13, 2025 - - Australian Biotech -
Chimeric Therapeutics reports strong early results from CHM CDH17 Phase 1/2 trial
November 13, 2025 - - Australian Biotech -
Australia joins global WHO task force to tackle antimicrobial resistance
November 13, 2025 - - Latest News
